426 related articles for article (PubMed ID: 32771986)
21. Impact of vaginal brachytherapy on survival in stage I endometrioid endometrial carcinoma.
AlHilli M; Amarnath S; Elson P; Rybicki L; Dowdy S
Int J Gynecol Cancer; 2020 Jun; 30(6):789-796. PubMed ID: 32184268
[TBL] [Abstract][Full Text] [Related]
22. Vaginal brachytherapy alone for patients with Stage II endometrial cancer with inner half cervical stromal invasion.
Barnes EA; Parra-Herran C; Martell K; Barbera L; Taggar A; Leung E
Brachytherapy; 2019; 18(5):606-611. PubMed ID: 31200993
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant therapy for grade 3, deeply invasive endometrioid adenocarcinoma of the uterus.
Onstad M; Ducie J; Fellman BM; Abu-Rustum NR; Leitao M; Mariani A; Multinu F; Lu KH; Soliman P
Int J Gynecol Cancer; 2020 Apr; 30(4):485-490. PubMed ID: 31980487
[TBL] [Abstract][Full Text] [Related]
24. Role of vaginal brachytherapy boost following adjuvant external beam radiotherapy in cervical cancer: Turkish Society for Radiation Oncology Gynecologic Group Study (TROD 04-002).
Gultekin M; Beduk Esen CS; Balci B; Alanyali S; Akkus Yildirim B; Guler OC; Yuce Sari S; Ergen SA; Sahinler I; Alsan Cetin I; Onal C; Yildiz F; Ozsaran Z
Int J Gynecol Cancer; 2021 Feb; 31(2):185-193. PubMed ID: 32998860
[TBL] [Abstract][Full Text] [Related]
25. Addition of External Beam Radiation Therapy to Adjuvant Chemotherapy for Patients With Stage IIIC Uterine Endometrioid Carcinoma: Utilization and Outcomes.
Nasioudis D; Taunk NK; Ko EM; Haggerty AF; Cory L; Giuntoli RL; Kim SH; Latif NA
Am J Clin Oncol; 2022 Sep; 45(9):373-378. PubMed ID: 35926158
[TBL] [Abstract][Full Text] [Related]
26. Absence of prognostic value of lymphovascular space invasion in patients with endometrial cancer and negative sentinel lymph nodes.
Matanes E; Eisenberg N; Lau S; Salvador S; Ferenczy A; Pelmus M; Gotlieb WH; Kogan L
Gynecol Oncol; 2021 Aug; 162(2):256-261. PubMed ID: 34119364
[TBL] [Abstract][Full Text] [Related]
27. Overuse of external beam radiotherapy for stage I endometrial cancer.
Wright JD; Margolis B; Hou JY; Burke WM; Tergas AI; Huang Y; Hu JC; Ananth CV; Neugut AI; Hershman DL
Am J Obstet Gynecol; 2016 Jul; 215(1):75.e1-7. PubMed ID: 26875941
[TBL] [Abstract][Full Text] [Related]
28. Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma.
Xiang M; English DP; Kidd EA
Gynecol Oncol; 2019 Sep; 154(3):487-494. PubMed ID: 31257010
[TBL] [Abstract][Full Text] [Related]
29. Pattern of recurrence in patients with endometrial cancer: A retrospective study.
Vizza E; Cutillo G; Bruno V; Sperduti I; Mancini E; Baiocco E; Chiofalo B; Cicchillitti L; Certelli C; Zampa A; Piccione E; Corrado G
Eur J Surg Oncol; 2020 Sep; 46(9):1697-1702. PubMed ID: 32204935
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics.
Young MR; Higgins SA; Ratner E; Yu JB; Mani S; Silasi DA; Azodi M; Rutherford T; Schwartz PE; Damast S
Int J Gynecol Cancer; 2015 Mar; 25(3):431-9. PubMed ID: 25621409
[TBL] [Abstract][Full Text] [Related]
31. External beam radiotherapy versus vaginal brachytherapy in patients with stage II endometrial cancer: a systematic review and meta-analysis.
Narasimhulu DM; Cope A; Riaz IB; Petersen I; Cilby W; Langstraat C; Glaser G; Kumar A; Cappuccio S; Murad MH; West C; Mariani A
Int J Gynecol Cancer; 2020 Jun; 30(6):797-805. PubMed ID: 32221021
[TBL] [Abstract][Full Text] [Related]
32. Role of adjuvant therapy after radical hysterectomy in intermediate-risk, early-stage cervical cancer.
Cao L; Wen H; Feng Z; Han X; Zhu J; Wu X
Int J Gynecol Cancer; 2021 Jan; 31(1):52-58. PubMed ID: 33303568
[TBL] [Abstract][Full Text] [Related]
33. Patterns of Failures and Clinical Outcome of Patients with Early-Stage, High-Risk, Node-Negative Endometrial Cancer Treated with Surgery Followed by Adjuvant Platinum-Based Chemotherapy and Vaginal Brachytherapy.
Laliscia C; Cosio S; Morganti R; Mazzotti V; Fabrini MG; Paiar F; Gadducci A
Oncology; 2019; 96(5):235-241. PubMed ID: 30904907
[TBL] [Abstract][Full Text] [Related]
34. Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma.
Hiura M; Nogawa T; Matsumoto T; Yokoyama T; Shiroyama Y; Wroblewski J
Int J Gynecol Cancer; 2010 Aug; 20(6):1000-5. PubMed ID: 20683408
[TBL] [Abstract][Full Text] [Related]
35. [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
Ma SK; Zhang HT; Sun YC; Wu LY
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):690-4. PubMed ID: 19173912
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant chemotherapy for stage I high-intermediate risk endometrial carcinoma with lymph-vascular invasion.
Nasioudis D; Oh J; Ko EM; Haggerty AF; Cory L; Giuntoli Ii RL; Kim SH; Morgan MA; Latif NA
Int J Gynecol Cancer; 2022 Jun; ():. PubMed ID: 35649658
[TBL] [Abstract][Full Text] [Related]
37. Survival benefit of radiation in high-risk, early-stage endometrioid carcinoma.
Xiang M; Kidd EA
J Gynecol Oncol; 2020 Jul; 31(4):e39. PubMed ID: 31912686
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional study.
Mahdi H; Rose PG; Elshaikh MA; Munkarah A; Isrow D; Singh S; Waggoner S; Ali-Fehmi R; Morris RT; Harding J; DeBenardo R
Gynecol Oncol; 2015 Mar; 136(3):529-33. PubMed ID: 25575483
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study.
Kurnit KC; Nobre SP; Fellman BM; Iglesias DA; Lindemann K; Jhingran A; Eriksson AGZ; Ataseven B; Glaser GE; Mueller JJ; Westin SN; Soliman PT
Gynecol Oncol; 2022 Dec; 167(3):452-457. PubMed ID: 36243601
[TBL] [Abstract][Full Text] [Related]
40. Ultrastaging of 'negative' pelvic lymph nodes in patients with low- and intermediate-risk endometrioid endometrial cancer who developed non-vaginal recurrences.
Gill SE; Garzon S; Multinu F; Hokenstad AN; Casarin J; Cappuccio S; McGree ME; Weaver AL; Cliby WA; Keeney GL; Mariani A
Int J Gynecol Cancer; 2021 Dec; 31(12):1541-1548. PubMed ID: 34706876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
